|
MechanismEGFR antagonists |
|
|
|
|
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
评价重组抗狂犬病毒人源化单克隆抗体注射液(SYN023)与狂犬病疫苗联合用于Ⅲ级狂犬病暴露后人群的有效性和安全性的随机、双盲、阳性对照(HRIG)Ⅲ期临床试验
[Translation] A randomized, double-blind, positive-controlled (HRIG) phase III clinical trial to evaluate the efficacy and safety of recombinant anti-rabies virus humanized monoclonal antibody injection (SYN023) combined with rabies vaccine in people exposed to grade III rabies
比较评价SYN023与HRIG联合狂犬疫苗对Ⅲ级疑似狂犬病毒暴露患者的有效性和安全性。
[Translation] To compare and evaluate the efficacy and safety of SYN023 and HRIG combined with rabies vaccine in grade III patients suspected of rabies virus exposure.
LR004联合FOLFOX治疗转移性结直肠癌患者的耐受性、药代动力学、安全性和有效性的Ib/IIa期临床试验
[Translation] A Phase Ib/IIa clinical trial to evaluate the tolerability, pharmacokinetics, safety and efficacy of LR004 combined with FOLFOX in patients with metastatic colorectal cancer
评价不同剂量LR004联合FOLFOX在转移性结直肠癌患者中的耐受性、药代动力学、安全性和有效性,确定LR004联合FOLFOX用药时的最大耐受剂量(MTD)。
[Translation] To evaluate the tolerability, pharmacokinetics, safety, and efficacy of different doses of LR004 combined with FOLFOX in patients with metastatic colorectal cancer, and to determine the maximum tolerated dose (MTD) of LR004 combined with FOLFOX.
SYN023单用及SYN023联合狂犬病疫苗在健康受试者的单中心、平行、开放的安全性和药代/药效动力学的I期桥接临床试验
[Translation] A single-center, parallel, open-label Phase I bridging clinical trial of safety and pharmacokinetics/pharmacodynamics of SYN023 alone and SYN023 combined with rabies vaccine in healthy subjects
比较SYN023固定剂量单次给药及其联合狂犬病疫苗PEP流程在中国受试者与美国受试者的药物代谢动力学(PK)差异,为后续临床试验奠定基础。
[Translation] The pharmacokinetic (PK) differences of SYN023 fixed-dose single administration and its combination with rabies vaccine PEP process in Chinese and American subjects were compared to lay the foundation for subsequent clinical trials.
100 Clinical Results associated with Synermore Biologics(Beijing) Co., Ltd.
0 Patents (Medical) associated with Synermore Biologics(Beijing) Co., Ltd.
100 Deals associated with Synermore Biologics(Beijing) Co., Ltd.
100 Translational Medicine associated with Synermore Biologics(Beijing) Co., Ltd.